AAN 2024: Subcutaneous Ocrelizumab Noninferior to IV for Patients With Multiple Sclerosis
The treatment resulted in near-complete suppression of relapses and MRI lesions
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.